There are 449 resources available
31P - Myelosuppression risk from epidermal growth factor receptor-tyrosine kinase inhibitors, carboplatin chemotherapy, or both in EGFR mutated non-small cell lung cancer (NSCLC)
Presenter: Nicolas Girard
Session: Poster Display session
33P - Real-world data of furmonertinib for patients with advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
Presenter: Maolin Liu
Session: Poster Display session
34P - Updated data from Beamion LUNG-1, a phase (ph) Ia/b trial of the HER2-specific tyrosine kinase inhibitor (TKI), zongertinib (BI 1810631), in patients (pts) with HER2 mutation-positive (m+) NSCLC
Presenter: Yi-Long Wu
Session: Poster Display session
35P - Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer
Presenter: Oliver Gautschi
Session: Poster Display session
36P - Selpercatinib treatment beyond progression (PD) in RET fusion-positive NSCLC: Association with pattern of PD
Presenter: María José De Miguel Luken
Session: Poster Display session
37P - ReAlec interim analysis: An observational study to evaluate the real-world clinical management and outcomes of patients (pts) with advanced ALK+ NSCLC treated with alectinib
Presenter: Emilio Bria
Session: Poster Display session
38P - Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) from ALTA-1L
Presenter: Angelo Delmonte
Session: Poster Display session
39P - Evaluation of body mass composition (BMC) changes in metastatic ALK-positive non-small cell lung cancer (ALK-mNSCLC) patients treated with anti-ALK tyrosine kinase inhibitors (aALK-TKIs): Preliminary results
Presenter: Salvatore Grisanti
Session: Poster Display session
40P - Lorlatinib-associated weight gain and dyslipidaemia: A single centre UK experience
Presenter: Alexius John
Session: Poster Display session
41P - The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI treated NSCLC patients
Presenter: Fenneke Zwierenga
Session: Poster Display session